Lysergide tartrate (LSD) vs Mebufotenin (5-MeO-DMT)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Major Depressive Disorder

Shared mechanism: 5-HT2A receptor · full Major Depressive Disorder pipeline

Lysergide tartrate (LSD) · DT120

Developed by Definium Therapeutics

Phase 3 in Major Depressive Disordersmall molecule
Reliable signal

NCT06941844 · Phase 3 · active, not recruiting

Participants were randomized and the study was triple-blinded (participant, investigator, and outcomes assessor) against a placebo comparator, which minimizes bias from expectation effects common in psychedelic trials. The primary endpoint, change in a validated clinical depression severity scale (MADRS) at Week 6, showed a large and statistically significant improvement for the drug versus placebo (p<0.0001), meeting the pre-specified comparison in the favorable direction.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: September 2027 · NCT07592689 (registry estimate)

Reported efficacy

Change from Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Week 6 (Baseline to Week 6): Emerge (NCT06941844), primary endpoint LS mean change in MADRS total score at Week 6: DT120 ODT 100 µg -13.3 vs placebo -5.2; LS mean difference -8.1 points; p<0.0001. (met)

Result source: NCT06941844

Mebufotenin (5-MeO-DMT) · GH001

Developed by GH Research

Phase 2 in Major Depressive Disordersmall molecule
Partial signal

NCT05800860 · Phase 2 · completed

This randomized, quadruple-masked, placebo-controlled phase 2 trial assigned 81 patients with treatment-resistant depression to inhaled GH001 (mebufotenin) or placebo. The registered primary endpoint was the change in MADRS depression score from baseline to Day 7. The sponsor reported a placebo-adjusted reduction of 15.5 points at Day 8 (P<0.0001), so the primary endpoint was met. This result comes from a company filing and is not posted on ClinicalTrials.gov, and no power calculation was found.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Reported efficacy

Mean change in MADRS from Baseline to Day 7: Placebo-adjusted MADRS reduction from baseline at Day 8: -15.5 points (LS mean difference -15.5, effect size -2.0, P<0.0001) (met)

Result source: NCT05800860

Results for Major Depressive Disorder

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointLysergide tartrate (LSD)Mebufotenin (5-MeO-DMT)
MADRS, change (acute)—Trial running · NCT06941844—Not reported
CGI-S, change (acute)—Trial running · NCT06941844—Not reported
MADRS response—Trial running · NCT06941844—Not reported
MADRS remission—Trial running · NCT06941844—Not reported
Relapse (% of patients)—Trial running · NCT06941844—Not reported

MADRS, change (acute)

Lysergide tartrate (LSD)
—Trial running · NCT06941844
Mebufotenin (5-MeO-DMT)
—Not reported

CGI-S, change (acute)

Lysergide tartrate (LSD)
—Trial running · NCT06941844
Mebufotenin (5-MeO-DMT)
—Not reported

MADRS response

Lysergide tartrate (LSD)
—Trial running · NCT06941844
Mebufotenin (5-MeO-DMT)
—Not reported

MADRS remission

Lysergide tartrate (LSD)
—Trial running · NCT06941844
Mebufotenin (5-MeO-DMT)
—Not reported

Relapse (% of patients)

Lysergide tartrate (LSD)
—Trial running · NCT06941844
Mebufotenin (5-MeO-DMT)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Lysergide tartrate (LSD)
Emerge (NCT06941844), primary endpoint LS mean change in MADRS total score at Week 6: DT120 ODT 100 µg -13.3 vs placebo -5.2; LS mean difference -8.1 points; p<0.0001. NCT06941844 · Phase 3 · design grade: strong · publication or press release
IDS-SR (self-rated): -3.9 low-dose vs -11.8 high-dose, diff -7.9, p=0.059 (not significant). IDS-C (clinician-rated): -3.6 low-dose vs -12.9 high-dose, diff -9.2, p=0.023 corrected <0.05 (significant). 31 patients low-dose, 30 high-dose. NCT03866252 · Phase 2 · design grade: moderate · publication or press release

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Mebufotenin (5-MeO-DMT)

MADRS -15.5 score @ 1.142857wk
absolute change · score
No placebo or comparator arm
NCT05800860 · Phase 2 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lysergide tartrate (LSD)'s landscape · Mebufotenin (5-MeO-DMT)'s landscape